Market Overview

Morning Gainers for Mar. 6, 2014: PXLW, SGMO, ERII, RGSE, NAVB, PSTI

Related PXLW
Pixelworks Announces Public Offering of Common Stock
Morning Market Gainers
Related SGMO
Sangamo BioSciences Announces Presentation At The 2015 Stem Cell Meeting On The Mesa - 2:30pm PT on Wednesday, October 7, 2015
Sangamo BioSciences Reports Updated Clinical Data from ZFP Therapeutic® Program for HIV/AIDS at the 2015 Interscience Conference of Antimicrobial Agents and Chemotherapy
  • Pixelworks (NASDAQ: PXLW) - up 40% - Reported that sales to Apple represented more than 10% of revenue in 2013.
  • Sangamo Biosciences (NASDAQ: SGMO) - up 17% - Announced that first-in-man study of genome editing using Sangamo's ZFN technology published In NEJM. Treatment with Sangamo's ZFN-Modified T-Cells provided functional control of HIV without antiretroviral drugs.
  • Energy Recovery (NASDAQ: ERII) - up 30% - Reports Q4 EPS of $0.13 vs $0.08 est; revenue of $23.20M vs $21.37M est.
  • Real Goods Solar (NASDAQ: RGSE) - up 5% - Selected by eight additional Massachusetts communities to expand solar.
  • Harvard Apparatus Regenerative Technology (NASDAQ: HART) - up 7% - Momentum continuing in the stock that is up 94 percent in March including this mornings gains.
  • Navidea BioPharma (NYSE: NAVB) - up 9.7% - Reported Q4 loss of $0.10/share, vs loss of $0.08/share est. Closes $30M loan with Oxford Finance, issued warrants for 391K shares at $1.92/share, will use proceeds for Lymposeek commercialization.
  • Pluristem (NASDAQ: PSTI) - up 4.5% - Gets FDA approval for commercial scale cell manufacturing process.

Posted-In: News Movers


Related Articles (ERII + NAVB)

View Comments and Join the Discussion!

Get Benzinga's Newsletters